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Abstract: Glaucoma is characterized by a loss of retinal ganglion cells (RGC) which is associated with a decrease of visual 
function. Neuroprotective agents as a new therapeutic strategy could prevent the remaining neurons from apoptotic cell 
death. Previous studies have shown the involvement of the Cyclooxygenase (COX)-2 signalling in the apoptotic death of 
neurons. Herein we investigated the neuroprotective effect of COX-1/COX-2- and selective COX-2- inhibitors on apoptotic. 
R28, a neuroretinal cell line and determined the PGE2 levels by ELISA. Furthermore we investigated differences in protein 
expression in the cells after exposure to elevated pressure compared to untreated cells by ProteinChip analysis.
In addition, a protein proﬁ  ling study of the cells after exposure to elevated pressure was performed. The protein expression 
proﬁ  les were measured by SELDI-TOF (Surface Enhanced Laser Desorption/Ionization-time of ﬂ  ight) Protein Chips. The 
protein identiﬁ  cation was performed by mass spectrometry (MS).
It could be shown that COX-2 inhibition signiﬁ  cantly prevented the cells from apoptosis and reduced the PGE2 concentra-
tions. Selective COX-2 inhibitors were signiﬁ  cant more potent than non-selective inhibitors or COX-1 inhibitors. We found 
differently expressed protein patterns in neuroretinal cells cultured at atmospheric pressure compared to those cells exposed 
to elevated pressure with or without celecoxib respectively. We identiﬁ  ed three biomarkers, ubiquitin, HSP10 and NDKB, 
which were differently expressed in the groups. However, our data indicates a distinct neuroprotective effect of COX-2 
inhibition. The local treatment with selective COX-2 inhibitors might provide an innovative strategy of therapeutic interven-
tion for glaucoma.
Keywords: retinal ganglion cells, cyclooxygenase, PGE2, apoptosis, neuroprotection, Seldi/Maldi, biomarker neuroprotection 
of apoptotic neuroretinal cells
Introduction
Glaucoma is one of the most frequent causes of irreversible blindness both in industrialized countries 
and worldwide (Quigley, 1996; Coleman, 1999). Intraocular pressure (IOP) appears to be one of the 
most important risk factors for the progression of the disease. The IOP increases in persons without any 
subjective symptoms until irreversible damage occurs. Untreated it leads to impaired vision and ulti-
mately to blindness in approximately 2% of the elderly population (Quigley, 1996; Coleman, 1999). 
Nowadays, IOP can be treated by lowering the intraocular pressure by e.g. timolol. However, raised 
intraocular pressure (IOP) is not the sole factor responsible for glaucomatous retinal damage. Only 10% 
of patients with increased IOP develop glaucomatous damage within 5 years (Kass et al. 2002), and it 
is commonly believed that up to 30% of patients with open angles and glaucomatous visual ﬁ  eld defects 
have normal-tension glaucoma (NTG) (Hoyng et al. 2002), and there are patients where the glaucoma 
continues to progress despite a successful lowering of the IOP. A number of other risk factors or patho-
genic mechanisms have been implicated in glaucoma, particularly in NTG, including vascular, mechan-
ical and genetic aspects as well as myopia, endocrine abnormalities, or autoimmune phenomena (Osborne 
et al. 2001). These observations have been the basis for the assessment of new therapeutic options for 
glaucoma. Glaucomatous optic neuropathy is characterized by an apoptotic loss of retinal ganglion 388
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cells. Currently, only one multicentered and 
appropriately powered clinical trial, of the non-
competitive N-methyl-D-aspartate (NMDA) 
antagonist, memantine (which already is Food and 
Drug Administration–approved for use in the 
United States for moderate-to-severe Alzheimer 
disease), assesses neuroprotection in glaucoma 
(Yucel et al. 2006). Memantine blocks the persis-
tent activation of receptors by the excitatory amino 
acid glutamate. It has a neuroprotective effect in 
animal models of optic nerve injury (Wolde Mussie 
et al. 2002) and glaucoma (Hare et al. 2004). The 
hyperstimulation of NMDA receptors (Choi, 1992) 
lead to a massive Ca
2⊕ inﬂ  ux that activates, among 
other processes, the Ca
2⊕-dependent phospholi-
pases A2 (PLA2). These PLA2 cleave membrane 
phospholipids to yield arachidonic acid, which is 
converted by cyclooxygenases (COXs) into pros-
taglandins (Hurley et al. 2002).
Two isoenzymes of COX have been identiﬁ  ed 
(Vane et al. 1998). COX-1 is constitutively 
expressed in most tissues and is thought to mediate 
“housekeeping” functions. On the other hand, 
COX-2, an inducible enzyme, participates in the 
injury/inﬂ  ammatory response (Vane et al. 1998; 
Smith et al. 1996). Among two isoenzymes of 
COX that have been identified, COX-2 has 
received more attention in the past, because it is 
inducible and is also constitutively expressed in 
brain and in a few other tissues (Vane et al. 1998; 
Dubois et al. 1998). Growing evidence, however, 
suggests that the functional significance of 
COX-2 is far beyond what was initially revealed 
(Vane et al. 1998; Dubois et al. 1998; Bazan, 2001; 
Ho et al. 1999). In the brain, COX-2 is expressed 
in discrete populations of neurons, is enriched in 
the cortex and hippocampus (Yamagata et al. 
1993), and has been implicated in brain functions 
and in neurologic disorders, including stroke, sei-
zures, and Alzheimer’s disease (Ho et al. 1999; 
Hewett et al. 2000; Iadecola et al. 2001; Miettinen 
et al. 1997; Nakayama et al. 1998).
The involvement of COX-2 in acute and chronic 
neurodegenerative syndromes has promoted the 
development of neuroprotective treatment strategies 
involving COX inhibitors, such as the non-steroidal 
anti-inﬂ  ammatory drugs (NSAIDs). Although epi-
demiological studies suggest that NSAIDs may be 
protective in chronic neurodegenerative conditions 
(McGeer et al. 1996), however, up to now very few 
is known about the mechanisms of neuroprotection 
mediated by COX inhibitors in glaucoma.
Therefore our approach investigated the 
neuroprotective effects of different COX-1/COX-2- 
and selective COX-2- inhibitors in a cell culture 
model, where apoptosis was induced in a neuro-
retinal cell line (R28) (Table 1, Tacconelli S. et al. 
2002). Furthermore, in order to assess the underly-
ing mechanisms of possible neuroprotective effects 
a protein proﬁ  ling study of R28 cells after exposure 
to elevated pressure (112 mmHg) was performed. 
Additionally, the PGE2 concentrations of the pres-
surized cells were analysed. The protein expression 
proﬁ  les were measured by SELDI-TOF (Surface 
Enhanced Laser Desorption/Ionization-time of 
ﬂ  ight) ProteinChips using different surfaces. The 
identiﬁ  cation of the proteins which are up-or down-
regulated was performed by MALDI-TOF (Matrix- 
Assisted Laser Desorption/Ionization-time of 
ﬂ  ight) analysis after tryptic digestion.
Materials and Methods
Cell cultures
R28 cells were cultured in Dulbecco’s Modiﬁ  ed 
Eagle Medium (DMEM; Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany) with 10% (v/v) FBS 
(fetal bovine serum, Bio Whittaker, Cambrex 
Bioscience, Verviers, Belgium), 1x MEM non-
essential amino acids (GIBCO, Invitrogen corpo-
ration), 1x MEM vitamins (GIBCO, Invitrogen 
corporation), 0.37% sodium bicarbonate, 0.058% 
L-glutamine and 100 mg/ml gentamicin. These 
cells have been shown to express proteins 
Table 1. This table summarizes the IC50 (COX-1/COX-2) 
ratios of different COX inhibitors.
Compound IC50 Ratio
(COX-1/COX-2)
Selectivity
Ibuprofen 0.5
Non selective
COX-Inhibitors
Naproxen 0.5
Salicylic acid 1
Indomethacin 1.9
Piroxicam 3.1 Preferential
COX-2 
Inhibitors
Meloxicam 11
Diclofenac 19
Celecoxib 30 Selective
COX-2 
Inhibitors
Rofecoxib 276
DFU 660389
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immunoreactive with glial markers (GFAP, S-100 
and vimentin), photoreceptor markers (IRBP, 
S-Ag, recoverin), ganglion cell marker (2G12), as 
well as Müller cell marker (RetG1) (Seigel et al. 
1996; Seigel, 1996). Cell cultures were maintained 
at 37 °C and 5% CO2 in air in a humidiﬁ  ed incuba-
tor. The culture medium was replaced every two 
days. Conﬂ  uent cultures were passaged using a 1x 
non-enzymatic cell dissociation solution (Sigma-
Aldrich, Munich, Germany).
Reagents
Acetylic salicylic acid (ASA), meloxicam and 
diclofenac were purchased from Sigma-Aldrich, 
Munich, Germany. DFU (5,5-dimethyl-3-
(3-fluorophenyl)-4-(4-methyl-sulphonyl) 
phenyl-2(H)-furanone), rofecoxib and celecoxib 
were synthesized and characterized according to 
literature at the Institute of Pharmacy, Department 
of Pharmaceutical and Medicinal Chemistry, Uni-
versity of Mainz, Germany (Li et al. 1999; Thérien 
et al. 2001; Penning et al. 1997).
WST-1 assay
This colorimetric assay quantiﬁ  es the number of 
metabolically active cells based on the cleavage 
of the tetrazolium salt WST-1(4-(3-(4-Iodophenyl)-
2-(4-nitrophenyl)-2H-5-tetrazolio)-1.3-benzene 
disulfonate) to formazan. The assay was per-
formed according to the manufacturer’s 
instructions. Absorbance from the resultant 
coloured solution was measured at a wavelength 
of 450 nm with background subtraction at 620 nm 
with a microplate spectrophotometer (ELISA 
reader, Multiskan Ascent, Thermo Electron 
Corporation).
Apoptosis induction
The cells were seeded in 96 well microtiter plates 
(2.8 × 10
5 cells/ml). After 24 hours, cells were 
grown to 40% conﬂ  uency. Apoptosis was induced 
by serum deprivation for 48 hours. To study the 
neuroprotective effect of different substances the 
cells were incubated with serum-free medium 
containing the drug at different concentrations for 
48 hours. After the incubation period the reduction 
in cell viability was measured by the colorimetric 
WST-1 (4-(3-(4-Iodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio)-1.3-benzene disulfonate)-test. In 
another experimental setting apoptosis was induced 
in the cells by exposure to elevated pressure 
(112 mmHg) for 48 hours. Cells were placed in a 
closed pressurized chamber (5% CO2) equipped 
with a manometer. No signiﬁ  cant impact on gas 
relationships in culture media as a result of pres-
surisation has been reported in similar pressure 
chamber based models (Agar et al. 2006). The 
elevated pressure was maintained for 48 hours. 
The cell viability was measured by the colorimet-
ric WST-1 test. Control cells from identical pas-
sage of cell lines were simultaneously placed in 
an incubator at atmospheric pressure at 37 °C. 
The viability of the cells was examined in the 
presence or absence of the drugs at different con-
centrations dissolved in culture medium contain-
ing 10% FCS.
Western blot analysis
Cultured cells were washed with ice-cold PBS, 
scraped from the culture dish in ice-cold lysis 
buffer containing 9.5 M urea, 2% CHAPS 
(3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate), 1% DTT (1.4 Dithiothreit) and 
protease inhibitors (protease inhibitor cocktail, 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). Lysates were sonicated and the cell 
homogenates were centrifuged at 13.000 × g for 
10 minutes. The protein concentration in the 
resultant supernatants was determined by the 
method of Lowry and equal amounts of protein 
were loaded on a 12% SDS polyacrylamide gel. 
The proteins were transferred to nitrocellulose 
membranes (Protran BA 83, Schleicher and 
Schuell, Germany) by using a semidry blotter 
(Biometra). Blot efﬁ  ciency was proved by revers-
ible staining with Ponceau red to visualize pro-
teins. The membranes were blocked with 5% 
dried minimal fat milk in PBS-Tween overnight. 
Membranes were then incubated with polyclonal 
antibodies against COX-1 (Alpha Diagnostic 
international, San Antonio, U.S.A.) and COX-2 
(Calbiochem). After incubation with peroxidase-
conjugated secondary antibody (Calbiochem) the 
signal was developed by staining with 0.05% 
4-chlor-1-naphthol (Sigma-Aldrich, Munich, 
Germany) with 0.015% hydrogen peroxide in 
20% methanol in TBS for 20 minutes. Molecular 
weights were estimated for each band based on 
the distance migrated for 10 known molecular 
weight standards (BenchMark, Invitrogen, 
Karlsruhe, Germany).390
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Annexin-V propidium iodide
The cell viability was analyzed by ﬂ  uorescence 
microscopy. We used the Annexin-V-FLUOS Stain-
ing Kit (Roche Diagnostics, Mannheim, Germany) 
a test kit for the detection and quantiﬁ  cation of 
apoptosis and differentiation from necrosis at single 
cell level. The analysis is based on the staining of 
apoptotic and necrotic cells with Annexin-V-Fluo-
rescein, which stains apoptotic as well as necrotic 
cells and propidium iodide, which stains necrotic 
cells only. Viable cells exclude propidium iodide 
and are annexin negative. The evaluation was done 
by ﬂ  uorescence microscopy with an excitation 
wavelength in the range of 450–500 nm (red) and 
detection in the range of 515–565 nm (green). The 
counting of the cells was performed by using the 
ImageJ software (available at http://rsb.info.nih.
gov/ij), by point to click counting method.
PGE2 quantitation assay to determine 
the concentration of PGE2
Concentrations of PGE2 were measured using 
speciﬁ  c ELISA kits (Correlate-EIATM kit, assay 
designs).
The RGC were placed in PS100 cell culture 
dishes. At the beginning of the experiment the cells 
were incubated for 30 minutes with acetylsalicylic 
acid (ASA; 30 μM) in cell culture medium (4 ml) 
in order to guarantee that the PGE2 concentration 
measured was only due to the activity of the 
COX-2. By ASA treatment the COX-1 is acetylated 
irreversibly at the Serin 529 and inactivated. Sub-
sequently, the RGC were washed 2x with 5 ml PBS 
and afterwards incubated with 4 ml cell culture 
medium alone or with 4 ml cell culture medium 
containing Celecoxib (5 μM) and pressurized for 
different periods of time (1, 3, 6, 24, and 48 h) 
(112 mmHg). At the end of the respective incuba-
tion period the supernatants were collected and the 
cells were counted after treatment with CDS solu-
tion using a Neubauer-chamber. The supernatants 
were centrifuged at 1200 RPM before the deter-
mination of the PGE2 was performed, in order to 
separate adherent cells.
The assay was performed according to the 
manufacturer’s protocol, using standard curves.
SELDI-TOF analysis
Cell lysates were prepared in 9.5 M urea, 2% 3-
[(3-cholamidopropyl)dimethylammonio]-1-pro-
panesulfonate (CHAPS), 1% DTT (1.4 Dithiothreit) 
and contained protease inhibitors (protease 
inhibitor cocktail, Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany). Lysis buffer was added to 
the plates and cells were scraped off and transferred 
to an eppendorf tube. After soniﬁ  cation and cen-
trifugation at 13.000 × g for 10 minutes the protein 
concentration in the resultant supernatants was 
determined by the method of Lowry. Samples 
containing 8 μg/1μl were analyzed on a weak 
cation exchange surface (CM10, Ciphergen Bio-
systems, Fremont, CA) and a reversed-phase sur-
face (H50, Ciphergen Biosystems, Fremont, CA). 
All Protein Chip Arrays were pretreated according 
to the standard protocols of the manufacturer. 2 μl 
of the samples were applicated on the spots, fol-
lowed by application of 2 × 1 μl matrix (sinapic 
acid in 0.15% TFA (triﬂ  uoroacetic acid)/50%  ACN 
(acetonitrile)). After drying the protein chips were 
measured in a SELDI-TOF (Surface Enhanced 
Laser Desorption/Ionization-time of flight) 
mass spectrometer (Ciphergen Biosystems Fre-
mont, CA). The mass analysis was performed 
according to an automated data collection protocol. 
Spectra were calibrated with external calibrants as 
described previously (Grus et al. 2005). Spectral 
intensities were normalized by total ion current 
(TIC). The CE manager software was used to nor-
malize the spectra, to automatically detect peaks, 
and to create the peak cluster lists. The cluster lists 
were exported to a statistical analysis program 
(Statistica). This program was used to perform a 
multivariate discriminant analysis to find a 
combination of most important biomarker (Grus 
et al. 2005).
Mass spectrometry
Protein identiﬁ  cation of differently expressed pro-
tein peaks was performed by mass spectrometry 
(MS). Therefore the cell lysates were separated by 
SDS polyacrylamide gel electrophoresis (NuPage 
12% Bis-Tris-Gel; Invitrogen), stained (Colloidal 
Blue Staining Kit; Invitrogen) and correspond-
ing bands were excised manually from the 
polyacrylamide gel and transferred into 1.5 ml 
reaction tubes. Excised gel pieces were treated with 
150 μl of 50% methanol/10% acetic acid and agi-
tated for 30 minutes, dehydrated with 70 μl aceto-
nitrile for 15 minutes, followed by extraction with 
50 μl of 50% formic acid/25% acetonitrile/15% 
isopropanol/10% water with vigorous shaking 
overnight. 2 μl of the extracts were applied to 391
Effects of cyclooxygenase inhibitors on apoptotic neuroretinal cells
Biomarker Insights 2008:3
CM10 and H50 ProteinChip arrays and reanalyzed 
with the ProteinChip Reader to conﬁ  rm the m/z 
values of the excised/extracted proteins. After-
wards, the gel extracts were vacuum dried (Con-
centrator; Eppendorf, Fremont, CA), 20 μl of 1% 
ammonia solution was added to the tubes, and the 
solution was vacuum dried again. 20 μl of 12 μg/1μl 
trypsin solution (Roche, Mannheim, Germany) 
were added to each tube and the samples incubated 
overnight at 37 °C. The peptide identiﬁ  cation was 
performed using a Maldi-TOFTOF (Matrix-
Assisted Laser Desorption/Ionization-time of 
flight) mass spectrometer (Ultraflex-Bruker 
Daltonics, Bremen, Germany). The Maldi spectra 
were exported and used for database searches with 
MASCOT (www.matrixscience.com/ Matrix 
Science, Boston, MA) using the NCBI (www.ncbi.
nlm.nih.gov, National Institutes of Health, 
Bethesda, MD) and SwissProt (http://www.wxpasy.
org/Swiss Institute of Bioinformatics, Geneva, 
Switzerland) databases.
Statistics
Data are represented as means of at least three iden-
tical experiments ± SEM. Statistical comparisons 
were performed with the unpaired Student’s Test.
Results
Identiﬁ  cation of COX-1 and COX-2
In order to verify the expression of COX-1 and 
COX-2 in the neuroretinal cells western blot analy-
sis was performed. The proteins were recognized 
by polyclonal antibodies to COX-1 and COX-2. 
After treatment with elevated pressure (112 mmHg) 
the protein expression was measured at 0 hours, 
2 hours, 6 hours, 24 hours and 48 hours. Extracts 
after 0 hours, 2 hours, 6 hours, 24 hours and 48 hours 
incubation time contained detectable amounts of 
COX-1 protein (approximately 70 kDa), COX-2 
protein (approximately 72 kDa) was present after 
48 hours of incubation whereas COX-2 was unde-
tectable in control cells. (Fig. 1 (A, B)).
Measurement of apoptosis 
inhibition by ﬂ  uorescence microscopy
To be sure that the treatment with serum-free 
medium leads mainly to an apoptotic cell death the 
Annexin-V/propidium iodide staining was per-
formed with subsequent ﬂ  uorescence microscopy 
to differentiate between apoptotic and necrotic 
cells. Additionally the effect of the treatment of the 
cells with serum-free medium containing the 
speciﬁ  c COX-2 inhibitor DFU (100 μM) compared 
to serum-free medium only for 48 hours was 
studied (Fig. 2).
After the Annexin-V/propidium iodide-staining 
the cells were counted utilizing the ImageJ soft-
ware by point to click counting method. DFU 
showed a distinct neuroprotective effect on apop-
totic R28 cells. The incubation of the cells with 
serum-free medium led to 42 ± 7% apoptotic cells 
and 20 ± 3% necrotic cells, the incubation with 
serum-free medium containing 100 μM DFU 
caused 23 ± 7% apoptotic cells and 11 ± 13% 
necrotic cells, whereas control cells which were 
incubated with culture medium (10% FCS) showed 
an apoptosis rate of only 0.4 ± 2% or necrosis 
0.2 ± 4% respectively (Fig. 3).
Measurement of cell viability 
by the WST-1 test
The neuroprotective effect of different COX-1 
and/or COX-2 inhibitors was determined by the 
AB
COX-1 COX-2
1 2 3 4 5 123 4 5
Figure 1. (A) Western blot analysis using polyclonal antibodies to COX-1 of cells treated with elevated pressure (112 mmHg). Temporal 
proﬁ  les of COX-1 expression are shown in the lanes: 1 = 0 h, 2 = 2 h, 3 = 6 h, 4 = 24 h, 5 = 48 h. Immunoreactivity did not change after the 
different time points. (B) Western blot analysis using polyclonal antibodies to COX-2 of cells treated with elevated pressure (112 mmHg). 
Temporal proﬁ  les of COX-2 expression are shown in the lanes: 1 = 0 h, 2 = 2 h, 3 = 6 h, 4 = 24 h, 5 = 48 h. Strong immunoreactivity for 
COX-2 was present after 48 h (lane 5); whereas COX-2 was undetectable in control cells (lane 1).392
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B
C
12 3
Figure 2. Representative phase contrast microscope images of cells that were incubated under different conditions for 48 h. (A) cells treated 
with culture medium containing 10% FCS, (B) cells treated with serum-free medium, (C) cells treated with serum-free medium containing 
DFU (100 μM). Column 1: phase contrast microscope images of cells under normal light conditions. Column 2: The red ﬂ  uorescent images 
show the propidium iodide stained necrotic cells. Column 3: The green ﬂ  uorescent images show the Annexin-V-stained apoptotic cells.
50
45
40
35
30
25
20
15
10
5
0
N
u
m
b
e
r
 
o
f
 
c
e
l
l
s
 
(
%
)
29
42
11
28
0.2
0.4
SF medium SF medium + DFU
100μM
Culture medium
(control)
Necrosis (%)
Apoptosis (%)
Figure 3. Number of apoptotic and necrotic neuroretinal cells after incubation under different conditions for 48 h. Cells treated with serum-
free medium, serum-free medium containing DFU (100 μM) and culture medium containing 10% FCS.  = necrotic cells in %,   = apoptotic 
cells in %. Total number of cells = 100% (SF medium and SF medium + DFU were signiﬁ  cantly different from control cells treated with medium 
containing 10% FCS (P  0.001 versus control)).393
Effects of cyclooxygenase inhibitors on apoptotic neuroretinal cells
Biomarker Insights 2008:3
colorimetric WST-1 test. Apoptosis was induced 
by incubating the cells with serum-free medium 
for 48 hours, which is a well established method 
for the induction of apoptosis (Seigel et al. 2000) 
and led to approximately 60% reduction in cell 
viability. Figure 4 shows the effects of acetylic 
salicylic acid (ASA), meloxicam, diclofenac, DFU 
and celecoxib on serum deprivated cells at differ-
ent concentrations.
At the clinical achievable concentration of 
10 μM (Niederberger et al. 2004) the specific 
COX-2 inhibitor celecoxib showed the maximal 
neuroprotective effect of all tested compounds, 
namely 81% more surviving cells compared to 
serum-free treated cells, followed by DFU, which 
protected 38% cells from apoptosis. Diclofenac 
could prevent 26% of the cells from undergoing 
apoptosis compared to incubation with serum-free 
medium only. The weakest effect possessed 
meloxicam and acetylic salicylic acid which both 
are unselective inhibitors of the COX isoforms. 
Only 20% or 5% respectively more cells survived 
compared to stimulation with serum-free medium 
(Fig. 5).
Measurement of apoptosis 
after exposure to elevated pressure
The viability of the cells incubated in the pres-
ence or absence of COX-1 and/or COX-2 
inhibitors at different concentrations dissolved 
in culture medium containing 10% FCS at ele-
vated pressure (112 mmHg/48 h) was examined. 
This treatment led to apoptosis in approximately 
58% cells. It was found that the selective COX-2 
inhibitor celecoxib showed a signiﬁ  cant decrease 
of cell death in a dose dependent manner. The 
specific COX-2 inhibitor celecoxib showed 
the maximal neuroprotective effect (18% more 
surviving cells vs control cells) at a concentra-
tion of 10 μM. ASA which is an unselective 
inhibitor of both COX isoforms could only pre-
vent 2.3% of the cells from undergoing apopto-
sis (Fig. 6).
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after 0 h or 48 h incubation period. The PGE2 synthesis of the celecoxib (5 μM) treated RGC was at each time point lower compared to 
untreated cells. RGC treated with the selective COX-2 inhibitor celecoxib (5 μM) showed a clear decrease in the PGE2 concentration com-
pared to untreated cells. After 48 hour incubation period (the same incubation period which was also used for the viability tests of the cells) 
the celecoxib treated RGC, showed an increase of the PGE2 synthesis around the factor 1.7 compared to the time point 0 h. In contrast in 
the same period of time the PGE2 concentrations of the untreated RGCs increased around the factor 4.6.
PGE2 quantitation
In order to examine, whether the pressure treatment 
(112 mmHg/48 h) of the RGC leads to a COX-2 
mediated increase of the prostaglandin E2 (PGE2) 
production, the PGE2 concentrations of the samples 
were determined after different incubation periods 
using the PGE2 kit (Correlate EIATM kit, assay 
Designs). Therefore the cells were prepared and 
incubated as described in the methods (2.7). By 
pre-treatment of the RGC with acetylsalicylic acid 
(30 μM), the COX-1 was irreversibly inhibited and 
it was guaranteed that the measured PGE2 was only 
due to the COX-2 activity. Figure 7A shows the 
expression of COX-2 in pressurized RGC in the 
presence or absence (control cells) of celecoxib 
(5 μM) after 48 h incubation period. When RGC 
expressing COX-2 were treated with celecoxib 
(5 μM), there was no appreciable change in the 
expression of COX-2. Figure 7B shows the PGE2 
synthesis of the pressurized RGC in the presence 
(black bars) or absence (white bars) (control cells) 
of celecoxib (5 μM) after 0 h or 48 h incubation 
period. RGC treated with the selective COX-2 
inhibitor celecoxib (5 μM) showed a clear decrease 
in the PGE2 concentration compared to untreated 
cells. After 48 hour incubation period (the same 
incubation period which was also used for the 
viability tests of the cells) the celecoxib treated 
RGC, showed an increase of the PGE2 synthesis 
around the factor 1.7 compared to the time point 396
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0 h. In contrast in the same period of time the PGE2 
concentrations of the untreated RGCs increased 
around the factor 4.6.
SELDI-TOF-MS analysis
The different protein- or peptide expression in cells 
exposed to elevated pressure (112 mmHg) in the 
absence or presence of the speciﬁ  c COX-2 inhibi-
tor celecoxib, respectively compared to cells cul-
tured at atmospheric pressure for 48 h were 
investigated.
The lysates of the three groups (1 = control cells 
at atmospheric pressure, 2 = cells at elevated pres-
sure cultivated in culture medium without cele-
coxib, 3 = cells at elevated pressure cultivated in 
culture medium containing celecoxib (5 μM)) were 
used for the analysis by SELDI-TOF and MALDI-
TOF (Fig. 8).
The protein proﬁ  ling results were analysed by 
means of multivariate analysis of discriminance 
and artificial neural network, in order to find 
possible “biomarker”, which are up- or down-
regulated due to the treatment options. A panel of 
42 protein peaks could be demonstrated that were 
signiﬁ  cantly differently expressed between the 
experimental groups.
The multivariate analysis of discriminance 
found signiﬁ  cant differences in overall protein 
expression in each group compared to the control 
group. The complex protein pattern of the control 
cells cultivated without pressurization (group 1) 
was different from cells exposed to elevated pres-
sure cultivated with (group 3) or without celecoxib 
(group 2). Furthermore the differences in protein 
expression comparing the group of pressurized 
cells without celecoxib (group 2) to those culti-
vated with celecoxib at a concentration of 5 μM 
(group 3) were investigated.
From these panels of more than 40 peaks, the 
analysis of discriminance revealed those as the 
most important to distinguish between the groups, 
which are listed in (Table 2).
The analysis of discriminance is able to calcu-
late a parameter, the canonical roots, which can 
basically be used to illustrate the quality of dis-
criminance between the groups. The closer the 
canonical roots of the protein pattern of each group, 
the more similar are the groups (Fig. 9) (Grus et al. 
2006).
To identify those proteins that revealed the high-
est degree of difference between the groups the 
cell lysates were separated by SDS polyacrylamide 
gel electrophoresis and the corresponding bands 
were tryptic digested and analysed by tandem mass 
spectrometry. The analysis was repeated three 
times and yielded the same results.
The biomarker at 8588 Da was identiﬁ  ed as 
ubiquitin. Ubiquitin was significantly lower 
expressed in those cells treated at atmospheric 
pressure (group 1) compared to the expression in 
both other groups (group 2 + 3). The expression of 
ubiquitin in pressurized cells without celecoxib 
treatment (group 2) was higher than in celecoxib 
treated cells (group 3) (Table 2, Fig. 8A).
The biomarker at 10833 Da was identiﬁ  ed as 
HSP10. Its highest expression was found in cells 
cultured at elevated pressure without celecoxib 
treatment (group 2). The expression was signiﬁ  -
cantly higher than in celecoxib treated cells (group 3). 
The lowest level was found in control cells culti-
vated at atmospheric pressure (group 1) (Table 2, 
Fig. 10 and Fig. 8B).
The biomarker at 13776 Da was identiﬁ  ed as 
nucleoside diphosphate kinase B (NDKB), a protein 
which is decreased in those cells treated with ele-
vated pressure (group 2 and 3) compared to the 
expression in control cells cultured at atmospheric 
pressure (group 1). The lowest protein level was 
found in cells treated with elevated pressure without 
celecoxib treatment (group 2) (Table 2, Fig. 8C).
Discussion
Nowadays, the treatment of glaucoma is mainly 
based on the reduction of the intraocular pressure. 
Neuroprotective drugs as a new approach however 
could protect the neurons which still not have been 
damaged and stop the progression of the disease.
In our studies we could demonstrate a distinct 
neuroprotective effect of COX-2 inhibition on 
apoptotic R28, a neuroretinal cell line. We showed 
that the speciﬁ  c COX-2 inhibitors celecoxib and 
DFU protected serum deprivated the cells in a dose 
dependent manner and were signiﬁ  cantly more 
potent than substances which inhibit preferentially 
the COX-1 or both COX-isoenzymes. Moreover, 
we could demonstrate a signiﬁ  cant dose-dependent 
decrease of cell death of pressurized cells treated 
with the selective COX-2 inhibitor celecoxib. The 
pressure conditions of 112 mmHg were selected 
analogous to levels seen in acute glaucoma. It is 
known that elevated pressure has an impact on 
different aspects of cellular anatomy and physiology. 397
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Figure 8. (A, B, C) SELDI-TOF patterns of cells treated at atmospheric pressure (1), cells after exposure to elevated pressure (2) and cells 
treated with celecoxib in a 5 μM concentration dissolved in culture medium at elevated pressure for 48 h (3), The sample containing 8 μg/1 μl 
were analyzed on different ProteinChip surfaces: a weak cation exchange surface (CM10) and a reversed-phase surface (H50). All Protein 
Chip Arrays were pretreated according to the standard protocols of the manufacturer. 2 μl of samples were applied on each ProteinChip 
position. After drying, 1 μl matrix solution (sinapic acid in 0.15% TFA (triﬂ  uoroacetic acid)/50% ACN (acetonitrile) ) was added twice. The 
ProteinChips were measured in a SELDI-TOF reader (PBSIIc, Ciphergen, Fremont, CA) with standardized laser conditions throughout the 
whole experiment. Spectra were normalized by total ion current (TIC). The graphs reveal the molecular weight (x-axis) vs the intensity 
(normalized ion current, y-axis). Each of the spectra groups above (1, 2, and 3) demonstrates the molecular weight of three different biomar-
kers at 8588, 10833, and 13766 Da.
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Figure 9. Canonical roots of the differently treated groups: 1 = cells at atmospheric pressure; 2 = cells at elevated pressure (112 mmHg); 
3 = cells at elevated pressure (112 mmHg) and celecoxib (5 μM). The canonical roots were calculated in the multivariate analysis of discri-
minance. This graph shows the quality of separation between the groups. Each point in this plot corresponds to one single sample. The 
closer the points are within this graph, the more similar the protein patterns of the samples were. The graph reveals clearly a good separa-
tion between the samples treated with and without elevated pressure, but demonstrates also a signiﬁ  cant effect between the cells treated 
with celecoxib or not.
Table 2. The table shows the most important peaks to distinguish between the groups. The ﬁ  rst six peaks represent 
the most signiﬁ  cant signals of the panel of more than 40 peaks. The biomarker label (e.g. 13776-CM10) consists of 
the molecular weight (e.g. 13776 Da) and the different ProteinChips, where the biomarker was found (e.g. CM10).
Analysis of variance, marked effects are signiﬁ  cant at p  0.05000 In:Ex:
AV group 1 AV group 2 AV group 3 p
13776-CM10 3.111 1.402 1.442 0.001
8588-CM10 4.880 9.282 9.123 0.001
4219-CM10 1.196 4.139 3.656 0.001
4216-H50 1.432 4.882 4.805 0.002
5147-H50 1.372 0.275 0.530 0.004
10833-CM10 1.019 2.225 1.807 0.006
5319-H50 1.103 0.332 0.543 0.041
10551-CM10 5.989 5.376 4.709 0.064
4828-CM10 1.203 1.644 0.649 0.096
6246-H50 3.017 2.588 3.385 0.132
3456-CM10 0.238 0.336 0.001 0.143399
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Different authors demonstrated morphological 
changes in cell shape, alignment and processes and 
cytoskeletal actin redistribution in various human 
ocular cells (Wax et al. 2000; Kosnosky et al. 
1995). However, very little is known about neuro-
nal apoptosis and hydrostatic pressure as an iso-
lated and independent stimulus. But different 
authors have already demonstrated apoptosis 
directly induced by hydrostatic pressure.
Previous studies have already shown the 
involvement of the COX-2 signaling pathways in 
the apoptotic death of neurons (Bagetta et al. 1998) 
Furthermore, an increased expression of COX-2 
in retinal neurons in response to glutamate excito-
toxicity, one of the mechanisms which is discussed 
being responsible for retinal ganglion cell death in 
glaucomatous optic neuropathy, was demonstrated 
(Strauss et al. 2002; Bazan et al. 1998). We con-
ﬁ  rmed the expression of COX-1 and COX-2 in the 
neuroretinal cells by western blot analysis. Earlier 
studies have already shown the existence of both 
isoforms in human eyes (Maihofner et al. 2001).
The mechanisms by which COX-2 is neurotoxic 
are poorly deﬁ  ned and controversial discussed but 
may be due to an increase in the production of 
prostanoids like prostaglandin E2 (PGE2).
Our studies showed that COX-2 positive pres-
surized RGCs synthesize PGE2. We observed 
differences between untreated and celecoxib-
treated RGC. Untreated cell cultures had ∼5 fold 
higher concentrations of PGE2, and COX-2 
inhibitor-treated cell cultures had minimal concen-
trations of PGE2: Celecoxib at a concentration of 
5 μM effectively prevented the production and 
release of PGE2.
On the one hand PGE2 (0.001–10 μM) is 
reported to protect cultured neurons from NMDA 
and glutamate induced death (Cazevieille et al. 
1994). This is in line with our ﬁ  ndings.
However, recently it was shown by Kawano 
et al. (Kawano et al. 2006) that PGE2 EP1 receptors 
are essential for the neurotoxicity mediated by 
COX-2-derived prostaglandin E2 in a mouse model 
in-vivo. Obviously the pro-death and pro-survival 
effects of PGE2 likely occur via the activation of 
different G-protein-coupled PGE2 receptors. Acti-
vation of the prostanoid EP2 receptor is normally 
associated with neuroprotection whereas in con-
trast the prostanoid EP1/EP3 receptor mediates 
COX-2 dependent neurotoxicity (Kawano et al. 
2006).
In contrast, many studies have shown that cele-
coxib exerts anticacinogenic effects in various 
cancer cell lines by inducing apoptosis, blocking cell 
cycle progression and angiogenesis. (Grösch et al. 
2006) This is excellently reviewed by Grösch et al. 
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2006. To clarify this discrepancy more studies are 
needed to investigate the differences in the regula-
tion of neuronal cells and cancer cells.
However, the biomarker at 8588 Da was identi-
ﬁ  ed as ubiquitin. Ubiquitin is a protein which plays 
a central role in degradation of short-lived and 
regulatory proteins important in a variety of basic 
cellular processes, including regulation of the cell 
cycle, modulation of cell surface receptors and ion 
channels, and antigen processing and presentation. 
A wide variety of neurodegenerative disorders are 
associated with the accumulation of ubiquitinated 
proteins as a result of disruption of the ubiquitin/
proteasome pathway in neuronal inclusions as well 
as in signs of inﬂ  ammation (Lowe et al. 2001). 
Disruption of the ubiquitin/proteasome pathway 
can result from damaging events, such as oxidative 
stress and production of neurotoxic molecules, 
from mutations or from an aging-induced decrease 
in proteasome function. In these neurodegenerative 
disorders, the abnormal protein aggregates may, 
themselves, trigger the expression of inﬂ  ammatory 
mediators, such as, COX-2 (Li et al. 2003). Our 
investigations showed that the highest expression 
of ubiquitin was found in pressurized cells without 
celecoxib treatment (group 2), whereas it was 
signiﬁ  cantly lower expressed in those cells treated 
at atmospheric pressure (group 1). Accordingly 
COX-2 inhibition seems to diminish the disruption 
of the ubiquitin/proteasome pathway.
The biomarker at 10833 Da was identiﬁ  ed as 
the chaperonin HSP10. Its highest expression was 
found in cells cultured at elevated pressure without 
celecoxib treatment (group 2), the lowest level was 
found in control cells cultivated at atmospheric 
pressure (group 1). HSP10 is a relatively small 
HSP that works in conjunction with a 60 kD 
co-chaperonin protein (HSP60). The HSP10-
HSP60 complex is located in the mitochondrial 
matrix and folds newly translated proteins, re-fold 
partially denatured proteins, and facilitates degra-
dation of improperly folded proteins. It also regu-
lates transport of proteins across the mitochondrial 
membrane. The integrity of the mitochondrial 
membrane is very important since loss of mito-
chondrial membrane integrity can result in release 
of cytochrome c into the cytosol which can in turn 
lead to apoptosis via activation of the caspases 
(Hickey et al. 2000). In our investigations we found 
that celecoxib was able to diminish the increase of 
HSP10 release upon exposure to elevated pressure 
compared to non-treated cells.
Neurons possess a high number of mitochondria 
for the supply of the energy for synaptic transmis-
sion. Apoptosis of neurons for example retinal 
ganglion cells may be therefore closely related to 
mitochondrial dysfunction.
The biomarker at 13776 Da was identiﬁ  ed as 
nucleoside diphosphate kinase B (NDKB), a pro-
tein which is decreased in those cells treated with 
elevated pressure (group 2 and 3) compared to the 
expression in control cells cultured at atmospheric 
pressure (group 1). The lowest protein level was 
found in cells treated with elevated pressure with-
out celecoxib treatment (group 2).
Nucleoside diphosphate kinase (NDPK) is an 
enzyme that catalyzes the transfer of the terminal 
phosphate from nucleoside triphosphates to nucle-
oside diphosphates via formation of a high energy 
phosphorylated enzyme intermediate. Several 
reports have suggested that the expression and/or 
activity of NDPK could modulate neuronal cell 
proliferation, differentiation, and neurite out-
growth. It was recently shown that the protein 
expression levels of NDKB in both down-syndrome 
and Alzheimer disease showed a moderate decrease 
(Kim et al. 2002). These ﬁ  ndings are in line with 
our investigations.
In conclusion, we identiﬁ  ed ubiquitin, HSP10 
and NDKB as biomarkers which are involved in 
the complex mechanism of neuroprotection medi-
ated by COX-2 inhibition after pressure induced 
apoptosis of R28 cells. From more than 40 differ-
ently expressed proteins we identiﬁ  ed in our pilot 
study three of the most important peaks to distin-
guish between the differently treated groups. Fur-
ther identiﬁ  cations have to clarify which role the 
various biomarkers play in determining the fate of 
apoptotic retinal ganglion cells.
In summary, our ﬁ  ndings provide further evi-
dences for better understanding the pathological 
mechanisms due to elevated pressure in neurode-
generative diseases like glaucoma. Nevertheless, 
our cell culture model does not exactly reﬂ  ect the 
situation in glaucomatous eyes because an ele-
vated pressure of 112 mmHg corresponds to those 
seen in acute glaucoma only, but this pilot study 
can help to understand the mechanism how 
COX-2 inhibitors mediate their neuroprotective 
effect.
Besides further investigations in animal studies 
have to be performed and clinical studies have to 
clarify if the identiﬁ  ed biomarkers will be found 
in glaucoma patients as well.401
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The speciﬁ  c COX-2 inhibitors that are nowadays 
systemically used in the therapy of pain are often 
correlated with some unwanted cardial side effects 
and therefore their use is currently controversially 
discussed among the experts (Grosser et al. 2006). 
However, the local treatment with selective 
COX-2 inhibitors in glaucoma could provide an 
innovative therapeutic intervention and could open 
up a complete new ﬁ  eld of indication for existing 
COX-2 inhibitors avoiding these dangerous side 
effects.
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